SPRUCE BIOSCIENCES, INC.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
SPRB$46.67-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(24,320) | $(29,477) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 882 | 4,387 |
| Depreciation and amortization | 16 | 37 |
| Non-cash lease expense | 199 | 183 |
| Loss on disposal of property and equipment | — | 2 |
| Change in fair value of warrant liability | (517) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,606 | 1,855 |
| Other assets | — | 85 |
| Accounts payable | 91 | (1,533) |
| Accrued expenses and other current liabilities | (4,310) | (6,439) |
| Deferred revenue | — | (4,214) |
| Other liabilities | (518) | (173) |
| Net cash used in operating activities | (26,871) | (35,287) |
| Cash flows from financing activities | ||
| Proceeds from exercise of common stock options | — | 180 |
| Proceeds from issuance of common stock related to employee stock purchase plan | 3 | 52 |
| Repayment of term loan | (1,216) | (1,216) |
| Tax withholding payments on restricted stock units | — | (13) |
| Net cash used in financing activities | (1,213) | (997) |
| Net decrease in cash, cash equivalents, and restricted cash | (28,084) | (36,284) |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,788 | 96,374 |
| Cash, cash equivalents, and restricted cash at end of period | $10,704 | $60,090 |
| Reconciliation of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $10,669 | $60,055 |
| Restricted cash, long-term (included in other assets) | 35 | 35 |
| Total cash, cash equivalents, and restricted cash | $10,704 | $60,090 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.